Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.55 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29614831 | 1.00 | NR2E1 (0.55) | NR2E1CYP2E1CYP2A6MAPTKDM4E | |
| SCHEMBL29431739 | 0.79 | CYP2E1 (0.54) | NR2E1CYP2E1CYP2A6MAOAMAOB | |
| SCHEMBL12146179 | 0.79 | KDM2B (0.55) | NR2E1CYP2E1CYP2A6MAPTKDM4E | |
| SCHEMBL9451324 | 0.79 | CYP2E1 (0.54) | NR2E1CYP2E1CYP2A6MAOAMAOB | |
| SCHEMBL3562687 | 0.79 | CYP2E1 (0.54) | NR2E1CYP2E1CYP2A6MEN1ALDH1A1 | |
| SCHEMBL3779157 | 0.79 | MAPT (0.52) | NR2E1MAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL264998 | 0.78 | CYP1A2 (0.56) | NR2E1CYP2E1CYP2A6MAPTMAOA | |
| SCHEMBL22199096 | 0.78 | CYP2E1 (0.53) | CYP2E1CYP2A6MAPTALDH1A1MAOA | |
| SCHEMBL2283022 | 0.77 | CYP2E1 (0.65) | NR2E1CYP2E1CYP2A6MAOAMAOB | |
| SCHEMBL12354425 | 0.77 | NR2E1 (0.65) | NR2E1CYP2E1CYP2A6ALDH1A1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4650002-A1 | ANILINE-BASED MODULATORS OF THE NUCLEAR RECEPTOR TLX (NR2E1) | Ludwig-Maximilians-Universität (DE) | 2025-11-19 | — | — | EP | disclosed |
| WO-2025229046-A1 | SUBSTITUTED HYDROQUINOLINES FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME | MOLIUS SAGLIK TEKNOLOJILERI ANONIM SIRKETI (TR) | 2025-11-06 | — | — | WO | disclosed |
| EP-4644375-A1 | SUBSTITUTED HYDROQUINOLINES FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME | Molius Saglik Teknolojileri Anonim Sirketi (TR) | 2025-11-05 | — | — | EP | disclosed |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-26 | — | — | US | disclosed |
| WO-2020168148-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-20 | — | — | WO | disclosed |
| US-20200131129-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. | 2020-04-30 | — | — | US | disclosed |
| US-20200131129-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. | 2020-04-30 | — | — | US | disclosed |
| US-20040266774-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-30 | — | — | US | disclosed |
| US-6770667-B1 | N-((IMIDAZOLYL)-PHENYL)-FLUORENE-1-CARBOXAMIDE DERIVATIVES; 5-HYDROXYTRYPTAMINE (5-HT) ANTAGONISTS; PSYCHOLOGICAL, NERVOUS SYSTEM, EATING, BRAIN AND SLEEP DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-03 | — | — | US | disclosed |
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| US-5432189-A | Bis-aryl amide and urea antagonists of platelet activating factor | AMERICAN CYANAMID COMPANY (US) | 1995-07-11 | — | — | US | disclosed |
| US-5350759-A | Bis-aryl urea compounds | WISSNER ALLAN (US) | 1994-09-27 | — | — | US | disclosed |
| US-5231182-A | Platelet activating factor inhibitor | AMERICAN CYANAMID COMPANY (US) | 1993-07-27 | — | — | US | disclosed |
| US-5225425-A | Respiratory system disorders | AMERICAN CYANAMID COMPANY (US) | 1993-07-06 | — | — | US | disclosed |
| US-5128351-A | BIS-ARYL AMIDE AND UREA ANTAGONISTS OF PLATELET ACTIVATING FACTOR | AMERICAN CYANAMID COMPANY (US) | 1992-07-07 | — | — | US | disclosed |
| US-5077409-A | Reducing hydroxy bis-aryl amide, acylating, hydrolyzing, sulfonating, halogenating, alkylating with nitrogen heterocycle | AMERICAN CYANAMID COMPANY (US) | 1991-12-31 | — | — | US | disclosed |
| EP-0458037-A1 | Bis-aryl amide and urea antagonists of platelet activating factor | AMERICAN CYANAMID COMPANY (US) | 1991-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131129-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | NR2E1 216/4885CYP2E1 379/4885CYP2A6 470/4885 |
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | NR2E1 326/4885CYP2E1 77/4885CYP2A6 210/4885 |
| US-20040266774-A1 | Amide compounds | TPH1, HTR1A, HTR5A | NR2E1 1288/4885CYP2E1 335/4885CYP2A6 241/4885 |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | NR2E1 202/4885CYP2E1 481/4885CYP2A6 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.